GET DAILY SIGNALS22nd Century Group (XXII) Shares Drop -92% in 30 Days Amid Heavy Dilution
Key Takeaways
- 22nd Century Group shares fell roughly 92% over the past 30 days, sliding from about $0.91 to about $0.07.
- The decline was amplified by aggressive equity issuance: an at-the-market offering expanded the share count more than fivefold in a single day in late October.
- Preliminary third-quarter results showed 66% sequential revenue growth and a return to positive gross profit, but the company remained deeply unprofitable with limited cash.
- The quarterly move was even steeper, down roughly 98%, extending a multi-year pattern of reverse stock splits and repeated dilution.
- Nasdaq minimum-bid compliance and the funding runway are now central risks for investors to monitor.
- For additional detail, explore XXII Price Targets, Earnings, and Forecast pages.
Company Snapshot: 22nd Century Group and Its Market Niche
22nd Century Group, Inc. operates as a tobacco products and plant-biotechnology firm based in Mocksville, North Carolina. It is primarily recognized for VLN, a proprietary cigarette with roughly 95% less nicotine than standard cigarettes, and it sells reduced-nicotine offerings under the VLN and Pinnacle brands. The business also earns revenue from contract manufacturing of cigarettes and filtered cigars for other companies.
Investors track XXII due to its unique regulatory stance. The FDA has approved reduced-nicotine claims for its combustible products, giving the firm an early position in what could become a low-nicotine tobacco segment. That potential is tempered by a modest revenue base, ongoing operating losses, and a track record of turning to dilutive equity financing that has kept the stock in distressed micro-cap territory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance: -92% Over 30 Days and -98% for the Quarter
Over the past 30 days, XXII declined roughly 92%. The shares closed near $0.91 in early October and fell to about $0.07 by early November, a move of approximately -91.9%. The drop was sharp rather than gradual, with several sessions posting single-day declines of more than 20%, including a drop of more than 46% in mid-October and a fall of more than 55% in one session in late October.
The quarterly trend was even more pronounced. From roughly $4.41 in early August to about $0.07 in early November, the stock lost approximately 98% of its value. This continued a longer multi-year downtrend, with the shares down well over 99% on a split-adjusted basis over the trailing year, reflecting repeated reverse splits and continuous share issuance rather than any single isolated event.
Main Driver Behind the Recent 30-Day Slide
The dominant catalyst was dilution. In late October, 22nd Century Group expanded its at-the-market offering program and issued shares into the open market at a rapid pace. According to the company’s prospectus supplement, shares outstanding rose from roughly 3.4 million on October 22 to more than 19.2 million the following day, an increase of more than fivefold in a single day, as the company sold approximately 15.8 million shares for roughly $4.7 million in gross proceeds. The program was subsequently expanded to allow up to an additional $18.8 million in sales.
Operational results, announced around the same time, told a mixed story. Preliminary unaudited third-quarter results reported net revenue up 66% sequentially to about $4.8 million, gross profit turning positive at roughly $0.4 million, and a narrowed net loss of about $2.6 million. Despite the improvement, the company remained unprofitable, and gross margin was roughly 8% on a small revenue base, leaving cash and equivalents near $3.9 million at quarter-end. The market focused on the capital-structure risk, and the shares fell sharply even as the revenue figures improved. From what I see, this financing pressure overshadowed the operational gains.
Quarterly Decline Reflects Ongoing Cycle of Splits and Issuance
The quarterly decline reflects a longer-running, self-reinforcing cycle. 22nd Century Group has repeatedly used reverse stock splits and equity sales to maintain its Nasdaq listing and fund operations, including a 1-for-20 reverse split in June 2026 and a 1-for-15 split earlier in 2026. Each round of issuance expands the share count and dilutes existing holders, while the reverse splits raise the nominal share price without adding underlying value.
Against that backdrop, investor concerns about the minimum bid price requirement, thin cash reserves, and the company’s ability to fund its VLN expansion strategy have kept selling pressure elevated. The fundamental progress in distribution and revenue has so far been outweighed by the persistent overhang of financing-related risk. I’m watching this closely as the pattern continues.
Forward-Looking Factors for XXII Investors
Investors monitoring XXII should focus on several forward-looking factors. First, the company’s upcoming third-quarter earnings report and any updated full-year guidance will be key tests of whether recent revenue momentum can be sustained. Second, any further ATM sales or new financing announcements will directly affect the share count and dilution outlook. Third, Nasdaq listing compliance, particularly the minimum bid price requirement, remains a live risk that could trigger additional reverse splits or delisting proceedings. Finally, the pace of VLN and Pinnacle distribution expansion, retailer adoption, and any regulatory developments around reduced-nicotine tobacco standards will shape the longer-term demand story. Each of these factors carries meaningful uncertainty, and none should be read as a recommendation to buy or sell the stock.
Exploring Automated Strategies with Tickeron
In my own analysis, I often turn to Tickeron’s AI Trading Bots to test automated approaches across volatile names like this one. The platform provides a range of data-driven strategies with varying timeframes and performance metrics, allowing users to compare options and select what fits their approach. It serves as a practical way to explore systematic tools without committing to any single signal.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
XXII in -28.32% downward trend, declining for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XXII declined for three days, in 428 of 441 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for XXII entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for XXII just turned positive on October 06, 2026. Looking at past instances where XXII's MACD turned positive, the stock continued to rise in 24 of 35 cases over the following month. The odds of a continued upward trend are 69%.
XXII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.003) is normal, around the industry mean (-7.598). P/E Ratio (0.000) is within average values for comparable stocks, (13.094). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.595). Dividend Yield (0.000) settles around the average of (0.059) among similar stocks. XXII's P/S Ratio (0.166) is slightly lower than the industry average of (2.780).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a plant biotechnology company
Industry Tobacco
Advertisement